TY - JOUR
T1 - The Heart-Brain Connection in Depression
T2 - Can it inform a personalised approach for repetitive transcranial magnetic stimulation (rTMS) treatment?
AU - Michael, Jessica A.
AU - Kaur, Manreena
N1 - Funding Information:
JM is supported by a Monash University Central Clinical School Bridging Scholarship . MK is supported by a National Health and Medical Research Council (Australia) Early Career Fellowship ( GNT111261 ) and a NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation (# 26366 ).
Publisher Copyright:
© 2021 Elsevier Ltd
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/8
Y1 - 2021/8
N2 - There is growing enthusiasm into the frontal-vagal network theory of major depressive disorder (MDD) and the potential role of a frontal-vagal network in the therapeutic mechanism of repetitive transcranial magnetic stimulation (rTMS) treatment for MDD. A review of the autonomic nervous system (ANS) in MDD and its role in antidepressant treatment for MDD is timely. The literature supports the well-established notion of ANS dysfunction in MDD and the benign effect of selective serotonin reuptake inhibitors, but not tricyclic antidepressants, on perturbed ANS function in MDD. Notwithstanding, there is some evidence that ANS measures have the capacity to inform response to antidepressant medication treatment. While there is a paucity of studies on the effects of rTMS on the ANS, critically, there is preliminary support that rTMS may alleviate ANS dysfunction in MDD and that ANS measures are associated with rTMS treatment response. These observations are consistent with the frontal-vagal theory of depression and the emerging literature on the use of ANS measures for personalising and optimising rTMS treatment of MDD.
AB - There is growing enthusiasm into the frontal-vagal network theory of major depressive disorder (MDD) and the potential role of a frontal-vagal network in the therapeutic mechanism of repetitive transcranial magnetic stimulation (rTMS) treatment for MDD. A review of the autonomic nervous system (ANS) in MDD and its role in antidepressant treatment for MDD is timely. The literature supports the well-established notion of ANS dysfunction in MDD and the benign effect of selective serotonin reuptake inhibitors, but not tricyclic antidepressants, on perturbed ANS function in MDD. Notwithstanding, there is some evidence that ANS measures have the capacity to inform response to antidepressant medication treatment. While there is a paucity of studies on the effects of rTMS on the ANS, critically, there is preliminary support that rTMS may alleviate ANS dysfunction in MDD and that ANS measures are associated with rTMS treatment response. These observations are consistent with the frontal-vagal theory of depression and the emerging literature on the use of ANS measures for personalising and optimising rTMS treatment of MDD.
KW - Antidepressants
KW - Autonomic nervous system
KW - Frontal-vagal network
KW - Major depressive disorder
KW - Repetitive transcranial magnetic stimulation
UR - http://www.scopus.com/inward/record.url?scp=85105836320&partnerID=8YFLogxK
U2 - 10.1016/j.neubiorev.2021.04.016
DO - 10.1016/j.neubiorev.2021.04.016
M3 - Review Article
C2 - 33891972
AN - SCOPUS:85105836320
SN - 0149-7634
VL - 127
SP - 136
EP - 143
JO - Neuroscience and Biobehavioral Reviews
JF - Neuroscience and Biobehavioral Reviews
ER -